* Acidifying agents: Drugs that acidify the urine, such as ascorbic acid, increase urinary excretion of dextroamphetamine, thus decreasing the half-life of dextroamphetamine in the body. * Alkalinizing agents: Drugs that alkalinize the urine, such as sodium bicarbonate, decrease urinary excretion of dextroamphetamine, thus increasing the half-life of dextroamphetamine in the body. * CYP2D6 inhibitors: Hydroxylation via the cytochrome P450 enzyme CYP2D6 is the major pathway of metabolism of dextroamphetamine. Potent CYP2D6 inhibitors, such as paroxetine, fluoxetine, bupropion, and duloxetine, among others, may inhibit the metabolism of dextroamphetamine and thereby increase exposure to it. Studies characterizing this potential interaction are currently lacking. Concomitant use of<unk>  with CYP2D6 inhibitors may increase the risk of serotonin syndrome due to greater drug exposure according to the FDA label for<unk> . * Monoamine oxidase inhibitors: Concomitant use of MAOIs and central nervous system stimulants such as<unk>  can cause a hypertensive crisis.
Lisdexamfetamine
Etilamfetamine
Solriamfetol
Tropisetron
Medifoxamine
Cilansetron
Sertindole
Alosetron